Future Infectious Disease Nucleic Acid Testing

February 2012 | 360 pages | ID: I141C0CA9CDEN
Venture Planning Group

Abstracts

This 360-page report presents an overview of the clinical significance and market needs for major infectious diseases, as well as extensive listings of companies developing and marketing molecular diagnostic technologies and products.

Contains 360 pages and 20 tables

Contents

1. OVERVIEW

2. MAJOR INFECTIOUS DISEASES

  AIDS
    Structure and Composition
    Classification
    AIDS Origins
    Animal Lentivirus Systems
    Virus Receptors
    HIV Infections in Humans
      Pathogenesis and Pathology
    CD4T Lymphocytes and Memory Cells
    Monocytes and Macrophages
    Lymphoid Organs
    Neural Cells
    Viral Coinfections
      Clinical Findings
    Plasma Viral Load
    Pediatric AIDS
      Neurologic Disease
      Opportunistic Infections
      Cancer
    Immunity
      Virus Isolation
      Serology
      Viral Nucleic Acid/Antigen Detection
    Epidemiology
      Worldwide Spread of AIDS
      United States
      Routes of Transmission
    DNA Probes
      Overview
      Quantitative PCR
      In Situ PCR
      Needed Improvements
    Viral Load/Drug Resistance Testing
    Genotype and Phenotype Testing
    Blood Banking Considerations
  Adenovirus
    Background
    Diagnostic Tests
    Vaccines and Drugs
    Adeno-Associated Viruses (AAV)
  Anthrax/Bacillus Anthracis
    Background
    Diagnostic Tests
    Vaccines and Drugs
  Babesiosis
    Background
  BEA and Other Bartonella Diseases
    Background
    Diagnostic Tests
    Vaccines and Drugs
  Chagas Disease
    Background
  Campylobacter
    Background
    Diagnostic Tests
      Culture Identification
    Vaccines and Drugs
  Chlamydia
    Background
      Chlamydia psittaci
      Chlmaydia pneumoniae
      Chlamydia trachomatis
    Diagnostic Tests
    Vaccines and Drugs
  Creutzfeldt-Jakob’s Disease
    Background
    Blood Transmission
    Diagnostic Tests
    Major Commercial and Academic Players
      Bayer
      Disease Sciences/Bio Tec Global
      Imperial College School of Medicine
      Ortho-Clinical Diagnostics
      Pall
      ProMetic Life Sciences
      Proteome Sciences/Idexx
      Q-One Biotech
      Serono
      U.S. Agricultural Research Service
    Drugs
    Vaccines
  Cytomegalovirus
    Background
      Chorioretinitis
      Gastrointestinal
      Central Nervous System Disease
    Diagnostic Tests
    Vaccines and Drugs
  Ebola Virus
    Background
      Epidemiology
      Clinical Syndromes
    Diagnostic Tests
    Vaccines and Drugs
  EchoVirus
    Background
      Acute Aseptic Meningitisis
      Encephalitis
      Exanthems
      Respiratory Disease
      Myopericarditis
      Neonatal Infections
    Diagnostic Tests
    Vaccines and Drugs
  Encephalitis
    Background
    Diagnostic Tests
    Vaccines and Drugs
  Enteroviruses
    Background
    Diagnostic Tests
      Viral Isolation and Identification
      Antibody Tests
    Vaccines and Drugs
  Epstein-Barr Virus
    Background
    Diagnostic Tests
    Vaccines and Drugs
  Gonorrhea
    Background
    Diagnostic Tests
    Vaccines and Drugs
  Hepatitis
    Hepatitis A
    Hepatitis B
      Structure and Composition
      Replication
    Hepatitis C
    Hepatitis D (Delta)
    Hepatitis E
    Hepatitis G
    Hepatitis Infections Pathology
    Clinical Findings
    Laboratory Tests
      Hepatitis A
      Hepatitis B
      Hepatitis C
      Hepatitis D
      Hepatitis E
    Virus-Host Immune Reactions
    Epidemiology
      Hepatitis A
      Hepatitis B
      Hepatitis C
      Hepatitis D (Delta)
    Vaccines and Drugs
  Herpes Simplex Virus
    Background
    Diagnostic Tests
    Vaccines and Drugs
  Legionella
    Background
    Diagnostic Tests
    Vaccines and Drugs
  Lyme Disease
    Background
      Clinical Description
      Clinical Case Definition
      Laboratory Criteria for Diagnosis
      Case Classification
    Diagnostic Tests
    Vaccines and Drugs
  Malaria
  Mycoplasma
    Background
      Ureaplasma Urealyticum & Mycoplasma Hominis
    Diagnostic Tests
    Vaccines and Drugs
  Papillomaviruses/HPV
    Background
      HPV in Cancer
      Cervical Neoplasm
    Diagnostic Tests
    Vaccines and Drugs
      Prevention
  Parvovirus B19
    Background
      Microbiology
      Epidemiology
      Clinical Syndromes
      Erythema Infectiosum (Slapped Cheek)
      Adult Polyarthropathy
      Transient Aplastic Crisis
      Transient Pancytopenia
      Red Cell Aplasia in Immunocompromised
      Perinatal Infections
    Diagnostic Test
    Vaccines and Drugs
  Pneumonia
    Background
    Diagnostic Tests
    Vaccines and Drugs
  Polyomaviruses
    Background
    Diagnostic Tests
    Vaccines and Drugs
  Salmonellosis
    Background
    Diagnostic Tests
    Vaccines and Drugs
  Shigellosis
    Background
    Diagnostic Tests
    Vaccines and Drugs
  Streptococci
    Background
    Diagnostic Tests
    Vaccines and Drugs
      Group A Streptococci
      Group B Streptococci
  Toxoplasmosis
    Background
    Diagnostic Tests
    Vaccines and Drugs
  Tuberculosis
    Background
    Diagnostic Tests
      Microscopic Characteristics
      Cultural Characteristics
      Skin Tests
      MDRTB
    Vaccines and Drugs
  West Nile Virus
    Background
      Clinical Syndromes
    Diagnostic Tests
    Vaccines and Drugs
  Yersinia
    Background
    Diagnostic Tests
    Vaccines and Drugs

3. ANTIBIOTIC SUSCEPTIBILITY

List Of Tables

LIST OF TABLES

Table 1: Major Companies Developing or Marketing AIDS NAT and other Direct Identification Tests
Table 2: Major Companies Developing or Marketing Adenovirus NAT and other Direct Identification Tests
Table 3: Major Companies Developing or Marketing Campylobacter NAT and Other Direct Identification Tests
Table 4: Major Companies Developing or Marketing Chlamydia NAT and other Direct Identification Tests
Table 5: Major Companies Developing or Marketing CMV NAT and other Direct Identification Tests
Table 6: Major Companies Developing or Marketing EBV NAT and other Direct Identification Tests
Table 7: Major Companies Developing or Marketing Gonorrhea NAT and other Direct Identification Tests
Table 8: Major Companies Developing or Marketing Hepatitis NAT and other Direct Identification Tests
Table 9: Major Companies Developing or Marketing Herpes NAT and other Direct Identification Tests
Table 10: Major Companies Developing or Marketing Legionella NAT and other Direct Identification Tests
Table 11: Major Companies Developing or Marketing Lyme Disease NAT And Other Direct Identification Tests
Table 12: Major Companies Developing or Marketing Mycoplasma NAT And other Direct Identification Tests
Table 13: Major Companies Developing or Marketing Papilloma Virus NAT And Other Direct Identification Tests
Table 14: Major Companies Developing or Marketing Pneumonia NAT And other Direct Identification Tests
Table 15: Major Companies Developing or Marketing Salmonella NAT And other Direct Identification Tests
Table 16: Major Companies Developing or Marketing Shigella NAT And other Direct Identification Tests
Table 17: Major Companies Developing or Marketing Streptococci NAT And Other Direct Identification Tests
Table 18: Major Companies Developing or Marketing Toxoplasmosis NAT And Other Direct Identification Tests
Table 19: Major Companies Developing or Marketing Tuberculosis NAT And Other Direct Identification Tests